Screener
Immunome IMNM Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 31,106 | 48,845 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 113,171,396 and 113,133,199 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 1,370,678 | 1,362,496 |
| Accumulated deficit | (782,003) | (728,164) |
| Total stockholders’ equity | 588,686 | 634,343 |
| Total liabilities and stockholders’ equity | $619,792 | $683,188 |
Item 1. Financial Statements.
FAQ
- What is Immunome's retained earnings?
- Immunome (IMNM) reported retained earnings of -$782M in Q1 2026.
- How has Immunome's retained earnings changed year-over-year?
- Immunome's retained earnings decreased by 40.3% year-over-year, from -$557.41M to -$782M.
- What is the long-term trend for Immunome's retained earnings?
- Over 5 years (2020 to 2025), Immunome's retained earnings has grown at a 68.0% compound annual growth rate (CAGR), from -$54.39M to -$728.16M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Immunome's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude